| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MURRIETA, Calif.—After recently increasing its investment in diagnostics company Zonda to 41%, CLX Investment Company, Inc., announced the signing of a letter of intent to acquire all remaining issued and outstanding Zonda shares. Zonda, which specializes in medical and non-medical tests using a proprietary enzyme detection system, is expected to launch its first product in the United States at the end of Q1 2008.
 
"We expect that the combination of Zonda's innovative testing products and strong, experienced leadership will allow the company to become a significant player in the diagnostic testing industry," says Steven R. Peacock, CLX consultant CEO. "For these reasons, we have targeted Zonda to become the focus of operations in CLX Investment Company."
 
One area of particular expertise for Zonda is point-of-care (POC) platforms, which according to a February 2006 report by BCC Research, will see its U.S. market almost double in value by 2010 to more than $9.5 billion. The same report suggests that the global POC market was just over $9 billion in 2005.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Red tumor cells are shown against a teal backdrop showing attachment to tissue.

Decoding the tumor microenvironment with immune profiling

Integrating multiplexed immunohistochemistry with spatial analysis offers a practical way to uncover tumor-immune dynamics.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue